OsrhAAT 40 mg/kg IV ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
231	α1−アンチトリプシン欠乏症	1

231. α1−アンチトリプシン欠乏症

---

臨床試験数 : 93 /  薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05315921 (ClinicalTrials.gov)	March 22, 2022	30/3/2022	Study of OsrhAAT or Placebo in Healthy Volunteers	A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Ascending Doses of OsrhAAT in Healthy Volunteers	Emphysema Secondary to Congenital AATD	Drug: OsrhAAT 1 mg/kg IV;Drug: OsrhAAT 3 mg/kg IV;Drug: OsrhAAT 10 mg/kg IV;Drug: OsrhAAT 20 mg/kg IV;Drug: OsrhAAT 40 mg/kg IV;Drug: OsrhAAT 60 mg/kg IV	Healthgen Biotechnology Corp.	NULL	Recruiting	18 Years	55 Years	All	48	Phase 1	United States